AAAAAA

   
Results: 1-11 |
Results: 11
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
Authors: Gulbrandsen, N Wisloff, F Brinch, L Carlson, K Dahl, IM Gimsing, P Hippe, E Hjorth, M Knudsen, LM Lamvik, J Lenhoff, S Lofvenberg, E Nesthus, I Nielsen, JL Turesson, L Westin, J
Citation: N. Gulbrandsen et al., Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support, MED ONCOL, 18(1), 2001, pp. 65-77
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
Authors: Gulbrandsen, N Wisloff, F Nord, E Lenhoff, S Hjorth, M Westin, J
Citation: N. Gulbrandsen et al., Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma, EUR J HAEMA, 66(5), 2001, pp. 328-336
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients
Authors: Casassus, P Gibson, J Joshua, DE Matthews, J Diaz, JC Gertz, MA Kyle, R Leong, T Oken, MM Fritz, E Ludwig, H Corrado, C Lastiri, F Peest, D Grosbois, B Vela-Ojeda, J Avvisati, G Mandelli, F Petrucci, MT Capnist, G Child, JA Drayson, MT Dunn, J MacLennan, I Mellstedt, H Osterborg, A Rodjer, S Turesson, I Westin, J Bergsagel, D Browman, GP Shustik, C Zee, B Hjorth, M Holmberg, E Rodjer, S Turesson, I Westin, J Alison, R Clarke, M Elphinstone, P Evans, V Gray, R Hicks, C James, S MacKinnon, L Peto, R Richards, S Wheatley, K Blade, J Fontanillas, M San Miguel, J Aitchison, R Newland, AC Cunningham, D Malpas, J Powles, RL Montuoro, A Jacobson, J Salmon, S
Citation: P. Casassus et al., Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, BR J HAEM, 113(4), 2001, pp. 1020-1034
Serum osteoprotegerin levels are reduced in patients with multiple myelomawith lytic bone disease
Authors: Seidel, C Hjertner, O Abildgaard, N Heickendorff, L Hjorth, M Westin, J Nielsen, JL Hjorth-Hansen, H Waage, A Sundan, A Borset, M
Citation: C. Seidel et al., Serum osteoprotegerin levels are reduced in patients with multiple myelomawith lytic bone disease, BLOOD, 98(7), 2001, pp. 2269-2271
Renal failure in multiple myeloma: reversibility and impact on the prognosis
Authors: Knudsen, LM Hjorth, M Hippe, E
Citation: Lm. Knudsen et al., Renal failure in multiple myeloma: reversibility and impact on the prognosis, EUR J HAEMA, 65(3), 2000, pp. 175-181
Serum syndecan-1: a new independent prognostic marker in multiple myeloma
Authors: Seidel, C Sundan, A Hjorth, M Turesson, I Dahl, IMS Abildgaard, N Waage, A Borset, M
Citation: C. Seidel et al., Serum syndecan-1: a new independent prognostic marker in multiple myeloma, BLOOD, 95(2), 2000, pp. 388-392
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study
Authors: Lenhoff, S Hjorth, M Holmberg, E Turesson, I Westin, J Nielsen, JL Wisloff, F Brinch, L Carlson, K Carlson, M Dahl, IM Gimsing, P Hippe, E Johnsen, H Lamvik, J Lofvenberg, E Nesthus, I Rodjer, S
Citation: S. Lenhoff et al., Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study, BLOOD, 95(1), 2000, pp. 7-11
Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades
Authors: Hjorth, M Holmberg, E Rodjer, S Turesson, I Westin, J Wisloff, F
Citation: M. Hjorth et al., Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades, EUR J HAEMA, 62(4), 1999, pp. 271-277
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
Authors: Turesson, I Abildgaard, N Ahlgren, T Dahl, IM Holmberg, E Hjorth, M Nielsen, JL Oden, A Seidel, C Waage, A Westin, J Wisloff, F
Citation: I. Turesson et al., Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors, BR J HAEM, 106(4), 1999, pp. 1005-1012
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma
Authors: Stead, ML Brown, JM Velikova, G Kaasa, S Wisloff, F Child, JA Hippe, E Hjorth, M Sezer, O Selby, P
Citation: Ml. Stead et al., Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma, BR J HAEM, 104(3), 1999, pp. 605-611
Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials
Authors: Pasquali, S Maqueo, JD Vela, J Kyle, RA Leong, T Fritz, E Suciu, S Palva, IP Oivanen, T Corrado, C Lastiri, FJ Peest, D Kildahl-Andersen, O Maniatis, A Alison, R Clarke, M Evans, V Gray, R Greaves, E Hall, E Hicks, C James, S Peto, R Richards, S Sinclair, D Tooth, A Wheatley, K Avvisati, G Boccadoro, M Bugliosi, R Mandelli, F Petrucci, MT Pileri, A Tribalto, M Alexanian, R Delasalle, KB Child, J Dunn, J MacLennan, I Milligan, D Mellstedt, H Osterborg, A Hjorth, M Holmberg, E Rodjer, S Westin, J Kamiya, O Shimizu, K Bergsagel, DE Shustik, C Hippe, E Kjaersgaard, E Turesson, I Westin, J Riccardi, A Ucci, G Blade, J Fontanillas, M De Rosa, L Montuoro, A Bartolucci, AA Omura, GA Stagg, M Salmon, S Tangen, C Jacobs, P Wood, L Levy, LM
Citation: S. Pasquali et al., Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials, J CL ONCOL, 16(12), 1998, pp. 3832-3842
Risultati: 1-11 |